Guided treatment choices for older adults with acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years of age or older.
- You must have a diagnosis of acute myeloid leukemia (AML) or a related condition such as myeloid sarcoma or myelodysplastic syndrome (MDS) that is transforming into AML.
- You must be able to give informed consent to participate in the study.
- You must not have acute promyelocytic leukemia (APL), a specific subtype of AML.
- You must be willing to complete all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This study looks at how adults with acute myeloid leukemia (AML) are treated and how they fare over time. The goal is to better understand the disease and improve care.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.